All In Biotech

Drug Trial Radar · NCT01155466

A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)

A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3;Protocol No. P04938)

Last checked: Nov 20, 2026Latest source record: Nov 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 778 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

778

Actual

Start

Jul 14, 2010

Primary completion

Dec 20, 2012

Study completion Dec 20, 2012

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jul 1, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

When a patient with Parkinson's disease (PD) is initially treated with L-dopa or dopamine agonists, the symptoms of PD improve or disappear. After several years of taking L dopa or dopamine agonists, patients notice that their PD medications wear off sooner than when they first started taking them. This "wearing off" is characterized by the return of symptoms (i.e., tremor, slowness, and rigidity) and may occur over the course of a few minutes to an hour. When a patient's PD symptoms have returned, the patient is said to be in the "off" state. When the patient takes another dose of medication, and his/her PD symptoms improve or resolve, the patient is said to be in the "on" state. Antagonism of adenosine Type 2a receptors (A2a) may provide relief of PD symptoms. This trial will test the hypothesis that A2a receptor antagonism can lead to improvement in the function of PD participants taking a stable dose of L-dopa, as measured by a reduction in "off" time.

Conditions

  • Parkinson Disease

Interventions

  • Preladenant 2 mg tabletDrug

    one 2 mg tablet orally twice daily

  • Preladenant 5 mg tabletDrug

    one 5 mg tablet orally twice daily

  • Preladenant 10 mg tabletDrug

    one 10 mg tablet orally twice daily

  • Placebo to Preladenant TabletDrug

    one tablet orally twice daily

  • Rasagiline 1 mg capsuleDrug

    one 1 mg capsule orally in AM

  • Placebo to Rasagiline capsuleDrug

    one capsule orally in AM

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Mean "Off" TimeTime frame: Baseline and Week 12
  2. Numberof Participants With Systolic Blood Pressure >=180 mm HgTime frame: Up to Week 14
  3. Number of Participants With Diastolic Blood Pressure >=105 mm HgTime frame: Up to Week 14
  4. Number of Participants With Alanine Aminotransferase >=3 Times the Upper Limit of NormalTime frame: Up to Week 14
  5. Number of Participants With Aspartate Aminotransferase >=3 Times the Upper Limit of NormalTime frame: Up to Week 14
  6. Percentage of Participants With SuicidalityTime frame: Up to Week 12
  7. Change From Baseline at Week 12 in Epworth Sleepiness Scale (ESS)Time frame: Baseline and Week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.